Compare Newmont Corporation (NEM) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Pfizer Inc — how do they compare? Newmont Corporation trades at $118.02 (market cap $119.64B), while Pfizer Inc trades at $27.78 (market cap $159.59B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 58 Days and Pfizer Inc for 158 Days on average.
| NEM | PFE | |
|---|---|---|
Market Cap | $119.64B | $159.59B |
Volume | 4,343,460 | 30,937,010 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $29.02 |
52-Week Low | $78.63 | $23.67 |
Typical Hold Time | 58 Days | 158 Days |
Enterprise Value | $116.23B | $211.09B |
Dividend Yield | 0.92% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NEM trades at $115.55, down 0.72% on the day, with a bearish technical signal but strong fundamentals. Recent earnings beats and record free cash flow of $5.3B in H1 2026 highlight operational strength. The stock is supported by a 75.68% analyst buy rating and a consensus price target of $136.83, though it faces near-term resistance at $116.
The outlook remains positive given robust profitability and growth, but risks include gold price volatility and execution of per-share growth targets. Upside potential exists if the company continues to exceed earnings expectations and maintains its cash flow momentum.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
